Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-cf6xr Total loading time: 0 Render date: 2025-04-29T22:11:10.987Z Has data issue: false hasContentIssue false

27 - Acquired sideroblastic anemias

Published online by Cambridge University Press:  01 June 2011

James C. Barton ,
Corwin Q. Edwards ,
Pradyumna D. Phatak ,
Robert S. Britton  and
Bruce R. Bacon
By
James C. Barton ,
Corwin Q. Edwards ,
Pradyumna D. Phatak ,
Robert S. Britton  and
Bruce R. Bacon
James C. Barton
Affiliation:
University of Alabama, Birmingham
Corwin Q. Edwards
Affiliation:
University of Utah Medical Center
Pradyumna D. Phatak
Affiliation:
University of Rochester Medical Center, New York
Robert S. Britton
Affiliation:
St Louis University, Missouri
Bruce R. Bacon
Affiliation:
St Louis University, Missouri
James C. Barton
Affiliation:
University of Alabama, Birmingham
Corwin Q. Edwards
Affiliation:
University of Utah School of Medicine, Salt Lake City
Pradyumna D. Phatak
Affiliation:
University of Rochester Medical Center, New York
Robert S. Britton
Affiliation:
St Louis University, Missouri
Bruce R. Bacon
Affiliation:
St Louis University, Missouri
Get access

Summary

Acquired sideroblastic anemia is a heterogeneous group of disorders characterized by excessive accumulation of amorphous iron deposits in the mitochondria of erythrocyte precursors. Ring sideroblasts, the sine qua non of sideroblastic anemia, are erythroblasts in Prussian blue-stained marrow aspirates that have numerous iron-positive mitochondria that occur in a perinuclear distribution. In sideroblastic anemia, typical ring sideroblasts have a full or partial ring and usually comprise more than 5% of all erythroblasts (Chapter 25, Fig. 25.1a, b). Other erythroblasts in the same specimens may have markedly increased numbers of iron-positive mitochondria that do not form a perinuclear halo. Acquired sideroblastic anemias encompass two main categories: clonal hematopoietic stem cell disorders classified as myelodysplastic syndromes (MDS); and reversible types of sideroblastic anemia due to drugs, chemicals, or other factors. Heritable types of sideroblastic anemia are described in Chapter 25.

Acquired sideroblastic anemia due to myelodysplastic syndromes

Classification

Refractory anemia with ring sideroblasts (RARS) is characterized by erythroid dysplasia, mitochondrial accumulation of mitochondrial iron-containing ferritin (mitoferrin), defective erythroid maturation, and anemia; some patients also have elevated platelet counts. Other patients with MDS and ring sideroblasts are classified as having refractory cytopenias with multilineage dysplasia and ring sideroblasts (RCMD-RS). MDS in patients with either RARS or RCMD-RS may progress to excess marrow blasts (refractory anemia with excess blasts, RAEB) or acute leukemia.

Pathophysiology

Non-germline mutations in marrow stem cells underlie the pathogenesis of MDS, including MDS subcategories typically associated with ring sideroblasts.

Type
Chapter
Information
Handbook of Iron Overload Disorders , pp. 277 - 283
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Bottomley, SS. Sideroblastic anaemia. Clin Haematol 1982; 11: 389–409.Google ScholarPubMed
Bitran, J, Golomb, HM, Rowley, JD.Idiopathic acquired refractory sideroblastic anemia: banded chromosome analysis in six patients. Acta Haematol 1977; 57: 15–23.CrossRefGoogle ScholarPubMed
Cazzola, M, Barosi, G, Gobbi, PG, Invernizzi, R, Riccardi, A, Ascari, E. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988; 71: 305–12.Google ScholarPubMed
Hellström-Lindberg, E, Cazzola, M. The role of JAK2 Mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program 2008; 2008: 52–9.Google Scholar
Steensma, DP, Tefferi, A. JAK2 V617F and ringed sideroblasts: not necessarily RARS-T. Blood 2008; 111: 1748.CrossRefGoogle ScholarPubMed
Schmitt-Graeff, AH, Teo, SS, Olschewski, M, et al. JAK2 V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008; 93: 34–40.CrossRefGoogle ScholarPubMed
Hellstrom-Lindberg, E, Schmidt-Mende, J, Forsblom, AM, Christensson, B, Fadeel, B, Zhivotovsky, B. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001; 112: 714–26.CrossRefGoogle ScholarPubMed
Martin, FM, Prchal, J, Nieva, J, et al. Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia. Br J Haematol 2008; 143: 4460.CrossRefGoogle ScholarPubMed
Bottomley, SS. Iron overload in sideroblastic and other non-thalassemic anemias. In: Barton, JC, Edwards, CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 4422.CrossRefGoogle Scholar
Barber, M, Conrad, ME, Umbreit, JN, Barton, JC, Moore, EG. Abnormalities of flavin monooxygenase as an etiology for sideroblastic anemia. Am J Hematol 2000; 65: 1493.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
Gattermann, N, Retzlaff, S, Wang, YL, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood 1997; 90: 49612.Google ScholarPubMed
Ramirez, JM, Schaad, O, Durual, S, et al. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring sideroblasts. Br J Haematol 2009; 144: 251–62.CrossRefGoogle ScholarPubMed
Lakhal, S, Talbot, NP, Crosby, A, et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood 2009; 113: 1555–63.CrossRefGoogle ScholarPubMed
Tanno, T, Bhanu, NV, O'Neal, PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096–101.CrossRefGoogle ScholarPubMed
Murphy, PT, Mitra, S, Gleeson, M, Desmond, R, Swinkels, DW. Urinary hepcidin excretion in patients with low grade myelodysplastic syndrome. Br J Haematol 2009; 144: 451–2.CrossRefGoogle ScholarPubMed
Beris, P, Samii, K, Darbellay, R, et al. Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations. Br J Haematol 1999; 104: 97–9.CrossRefGoogle Scholar
Lindberg, EH. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes. Curr Drug Targets 2005; 6: 713–25.CrossRefGoogle ScholarPubMed
Tehranchi, R, Fadeel, B, Schmidt-Mende, J, et al. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res 2005; 11: 6291–9.CrossRefGoogle ScholarPubMed
Ljung, T, Back, R, Hellstrom-Lindberg, E. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors. Haematologica 2004; 89: 14463.Google ScholarPubMed
Bottomley, SS. Sideroblastic anemia: death from iron overload. Hosp Pract (Off Ed) 1991; 26 Suppl 3: 55–6.CrossRefGoogle ScholarPubMed
Bennett, JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008; 83: 858–61.CrossRefGoogle ScholarPubMed
Dreyfus, F. The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev 2008; 22 Suppl 2: S29–34.CrossRefGoogle ScholarPubMed
Platzbecker, U, Bornhauser, M, Germing, U, et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transpl 2008; 14: 1217–25.CrossRefGoogle Scholar
Wimazal, F, Nosslinger, T, Baumgartner, C, Sperr, WR, Pfeilstocker, M, Valent, P. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Invest 2009; 39: 406–11.CrossRefGoogle ScholarPubMed
Messa, E, Cilloni, D, Messa, F, Arruga, F, Roetto, A, Saglio, G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008; 120: 70–4.CrossRefGoogle ScholarPubMed
Metzgeroth, G, Dinter, D, Schultheis, B, et al. Deferasirox in MDS patients with transfusion-caused iron overload—a phase-II study. Ann Hematol 2009; 88: 301–10.CrossRefGoogle ScholarPubMed
Maggio, A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 2007; 138: 407–21.CrossRefGoogle ScholarPubMed
Steensma, DP. Myelodysplasia paranoia: Iron as the new radon. Leuk Res 2009; 33: 1158–63.CrossRefGoogle ScholarPubMed
DeLoughery, TG.Iron: The fifth horseman of the apocalypse? Am J Hematol 2009; 84: 263–4.CrossRefGoogle ScholarPubMed
Verwilghen, R, Reybrouck, G, Callens, L, Cosemans, J. Antituberculous drugs and sideroblastic anaemia. Br J Haematol 1965; II: 92.CrossRefGoogle Scholar
Sharp, RA, Lowe, JG, Johnston, RN. Anti-tuberculous drugs and sideroblastic anaemia. Br J Clin Pract 1990; 44: 706.Google ScholarPubMed
Hines, JD, Grasso, JA. The sideroblastic anemias. Semin Hematol 1970; 7: 86–106.Google ScholarPubMed
Harris, EB, MacGibbon, BH, Mollin, DL. Experimental sideroblastic anemia. Br J Haematol 1965; 11: 99.CrossRefGoogle Scholar
Lubran, MM. Lead toxicity and heme biosynthesis. Ann Clin Lab Sci 1980; 10: 402–13.Google ScholarPubMed
Schwartz, J, Landrigan, PJ, Baker, EL, Orenstein, WA, Lindern, IH. Lead-induced anemia: dose-response relationships and evidence for a threshold. Am J Public Health 1990; 80: 165–8.CrossRefGoogle ScholarPubMed
Conrad, ME, Barton, JC. Anemia and iron kinetics in alcoholism. Semin Hematol 1980; 17: 149–63.Google ScholarPubMed
Hines, JD, Cowan, DH. Studies on the pathogenesis of alcohol-induced sideroblastic bone marrow abnormalities. N Engl J Med 1970; 283: 441–6.CrossRefGoogle ScholarPubMed
Pierce, HI, McGuffin, RG, Hillman, RS. Clinical studies in alcoholic sideroblastosis. Arch Intern Med 1976; 136: 283–9.CrossRefGoogle ScholarPubMed
Beck, EA, Ziegler, G, Schmid, R, Ludin, H. Reversible sideroblastic anemia caused by chloramphenicol. Acta Haematol 1967; 38: 1–10.CrossRefGoogle ScholarPubMed
Firkin, FC. Mitochondrial lesions in reversible erythropoietic depression due to chloramphenicol. J Clin Invest 1972; 51: 2085–92.CrossRefGoogle ScholarPubMed
Beck, EA.[Blood damage due to chloramphenicol and thiamphenicol.]Schweiz Med Wochenschr 1975; 105: 1078–80.Google Scholar
Graham, GG, Cordano, A. Copper depletion and deficiency in the malnourished infant. Johns Hopkins Med J 1969; 124: 1390.Google ScholarPubMed
Joffe, G, Etzioni, A, Levy, J, Benderly, A. A patient with copper deficiency anemia while on prolonged intravenous feeding. Clin Pediatr (Phila) 1981; 20: 226–8.CrossRefGoogle ScholarPubMed
Spiegel, JE, Willenbucher, RF. Rapid development of severe copper deficiency in a patient with Crohn's disease receiving parenteral nutrition. J Parenter Enteral Nutr 1999; 23: 1692.CrossRefGoogle Scholar
Hirase, N, Abe, Y, Sadamura, S, et al. Anemia and neutropenia in a case of copper deficiency: role of copper in normal hematopoiesis. Acta Haematol 1992; 87: 195.CrossRefGoogle Scholar
Condamine, L, Hermine, O, Alvin, P, Levine, M, Rey, C, Courtecuisse, V. Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. Br J Haematol 1993; 83: 166–8.CrossRefGoogle ScholarPubMed
Perry, AR, Pagliuca, A, Fitzsimons, EJ, Mufti, GJ, Williams, R. Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol 1996; 64: 692.CrossRefGoogle ScholarPubMed
Ramselaar, AC, Dekker, AW, Huber-Bruning, O, Bijlsma, JW. Acquired sideroblastic anaemia after aplastic anaemia caused by D-penicillamine therapy for rheumatoid arthritis. Ann Rheum Dis 1987; 46: 156–8.CrossRefGoogle ScholarPubMed
Broun, ER, Greist, A, Tricot, G, Hoffman, R.Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA 1990; 264: 1441–3.CrossRefGoogle ScholarPubMed
Ramadurai, J, Shapiro, C, Kozloff, M, Telfer, M. Zinc abuse and sideroblastic anemia. Am J Hematol 1993; 42: 227–8.CrossRefGoogle ScholarPubMed
Fiske, DN, McCoy, HE, Kitchens, CS. Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome. Am J Hematol 1994; 46: 1470.CrossRefGoogle ScholarPubMed
Kumar, A, Jazieh, AR. Case report of sideroblastic anemia caused by ingestion of coins. Am J Hematol 2001; 66: 126–9.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
Brodsky, RA, Hasegawa, S, Fibach, E, Dunbar, CE, Young, NS, Rodgers, GP. Acquired sideroblastic anaemia following progesterone therapy. Br J Haematol 1994; 87: 859–62.CrossRefGoogle ScholarPubMed
Henrikson, KP, Gross, SC, Dickerman, HW. Effect of pyridoxal 5′-phosphate on oligodeoxynucleotide binding of mouse uterine cytosol estradiol-receptor complexes. Endocrinology 1981; 109: 1196–202.CrossRefGoogle ScholarPubMed
O'Brien, H, Amess, JA, Mollin, DL. Recurrent thrombocytopenia, erythroid hypoplasia and sideroblastic anaemia associated with hypothermia. Br J Haematol 1982; 51: 451–6.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×